Clinical Trial Search

Primary: PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared…

Primary: Opioid Consumption Dose 48h After Operation. — 37.4; 50.4 microgramme

Primary: Early Clinical Response Rate — 264; 266 Responders

Primary: The "Average Pain Over the Last 24 Hours" at Week 12 of the Double-blind Period — 3.86; 4.32 units on a scale (0 - 10) — p=0.0055

Primary: Insulin Sensitivity Index — 7.7; 7.7; 8.1; 7.8 (dL x L)/(mg x mIU) — p=0.930

Primary: Changes in GI Symptom Per Intervention Session — -0.24; -0.08; -0.09; -0.09 units on a scale

Primary: Change From Baseline in Mini-mental State Examination (MMSE) Total — 20.9; 18.6; 0.3; 2 Score on a Scale

Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: Percentage of Participants Demonstrating A Meaningful Clinical Response — 77 percentage of participants

Primary: Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection — 134; 449; 46; 160 participants

Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period…

Primary: Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7…

Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants

Primary: Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment — 21.54; 20.87 percentage of myocardium — p=0.29